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Summary: We present an overview  of the management o f pituitary adenomas, 
with discussions of microanatomy, o f diagnostic studies o f general neuroen­
docrine function, and of radiologic evaluation. We discuss the diagnosis o f 
pituitary adenoma and its treatment with sections on null cell, prolactin (PRL)- 
secreting, growth hormone (GH)-secreting, and corticotropin-secreting adeno­
mas and on other secreting tumors. For surgical management, we present an 
historical background and then focus on the transsphenoidal and transcranial 
approaches. The use of primary and postoperative radiotherapy (RT) is exam ­
in ed . K ey W ords: P itu itary ad enom a— P rolactin — G row th h orm one—  
Corticotropin— Transsphenoidal surgery— Transcranial surgery.
Pituitary adenomas are benign tumors that may 
originate from any of the native pituitary cell types. 
Pituitary adenoma is a common incidental sellar ab­
normality; autopsy and radiographic studies suggest 
that incidental microadenomas (lesions <10 mm in 
diameter) may be present in 10 to 20% of the pop­
ulation, but that macroadenomas (>10 mm) are 
rare. Contemporary imaging modalities, combined 
with the advent of the radioimmunoassay, have 
ushered in a new era in the diagnosis and manage­
ment of pituitary adenomas. Such contemporary di­
agnostic studies have rendered original morphomet- 
ric histological classifications of pituitary tumors 
clinically obsolete.
M ICROSCOPIC ANATOM Y
Norm al Anatom y and Physiology of  
the Adenohypophysis
The anterior pituitary contains connective tissue, 
fenestrated capillaries, and epithelial cells orga-
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nized in a glandular pattern (1-3). A description of 
the way distinct epithelial cell types may be char­
acterized by their secretory protein hormones fol­
lows.
G ro w th  H o r m o n e  P r o d u c in g  C ells
Somatotrophs, growth hormone (GH)-producing 
cells of the pituitary gland, comprise —50% of the 
normal adenohypophyseal cell population and are 
located in the lateral wings of the anterior lobe (3­
4). GH is a 191 amino acid polypeptide hormone 
that opposes the effect of insulin, stimulates the up­
take of amino acids, and causes a release of free 
fatty acids from tissue storage sites (5). In the liver 
and other tissues, GH also mediates the synthesis of 
insulin-like growth factors (IGFs), previously called 
somatomedins, that induce protein synthesis in the 
skeleton and muscle and glucose oxidation in adi­
pose tissue. IGFs also stimulate cell replication at 
these sites. The secretion of GH is stimulated by 
growth hormone-releasing hormone (GHRH) and 
inhibited by somatostatin. GH and insulin-like 
growth factor-1 (IGF-1) (also called somatomedin- 
C) stimulate the release of somatostatin, thereby 
down-regulating the secretion of GH. GH is se-
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creted in episodic surges occurring every 3 to 4 h; in 
young individuals, the greatest peaks occur after 
the onset of deep sleep. Stimuli of GH secretion 
include insulin-induced hypoglycemia, arginine, ex­
ercise, L-dopa, clonidine, propanolol, and GHRH.
P r o la c t in - P r o d u c in g  C e lls
The mammotropes, also called lactotropes, rep­
resent 15 to 25% of the anterior pituitary cells and 
populate the lateral gland (6,7). These cells increase 
during pregnancy and lactation and following estro­
gen therapy. Prolactin (PRL) is a 198 amino acid 
polypeptide known to facilitate the development of 
breast tissue to ensure the production of milk. PRL 
secretion is stimulated by thyrotropin-releasing hor­
mone (TRH), estrogens, stress, and exercise. Do­
pamine is acknowledged to be the principal prolac­
tin inhibitory factor.
A d r e n o c o r t i c o t r o p in - P r o d u c in g  C e lls
Corticotrophs constitute —20% of the adenohy- 
pophyseal cells. They lie within the mediolateral 
aspects of the pars distalis (3,8). Adrenocorticotro- 
pin (ACTH) is a 39 amino acid peptide that pro­
motes growth of the adrenal cortex and the synthe­
sis of hormones produced by this gland. ACTH also 
has melanotropic effects and is responsible for the 
pigmentation commonly seen in Nelson’s syndrome 
and Addison’s disease. ACTH is a fragment of pro- 
opiocortin. Both the corticotropic and the melano­
tropic cells cleave the pro-hormone into a common 
precursor containing 130 amino acids. Within the 
corticotroph there is further cleavage to form 
ACTH (1-39 amino acids) and 3-lipotropin ((3-LPH) 
(1-91 amino acids). Within the melanotroph, ACTH 
is cleaved into alpha-melanostimulating hormone 
(a-MSH) (1-13 amino acids) and corticotropin-like 
intermediate peptide; (3-LPH is cleaved further to 
form gamma-LPH (1-58 amino acids) and (3-endor­
phin (61-91 amino acids). In the human, the physi­
ological roles of the lipotropins, a-MSH, and (3-en­
dorphin, are unclear. The synthesis and secretion of 
ACTH is stimulated by corticotropin-releasing hor­
mone (CRH). Vasopressin, though a weak ACTH 
stimulant, directly potentiates the effect of CRH. 
The inhibition of ACTH release is regulated by the 
negative feedback effect of cortisol on the corti­
cotroph directly and on the release of CRH at the 
hypothalamus. ACTH also regulates the release of 
CRH through a short loop negative feedback effect.
The secretion of ACTH follows a circadian rhythm 
and occurs in brief episodes during the late sleep 
period and just before awakening. Rapid release of 
ACTH also occurs under the stimulation of stress 
such as pain, fear, noise, extreme cold, fever, hy­
poglycemia, and hemorrhage.
T h y ro x in -S t im u la t in g  H o r m o n e - P r o d u c in g  C ells
Thyrotrophs constitute —5% of the adenohy­
pophysis and are located in the anteromedial region 
(3,9). TSH is a glycoprotein composed of two non- 
covalently linked moieties, the alpha and the beta 
subunits. The beta subunit confers biological activ­
ity on the hormone. Thyrotrophs secrete not only 
TSH but also the separate subunits. TSH regulates 
the synthesis of thyroid hormones, thyroxine (T4) 
and triiodothyronine (T3), by the thyroid gland. A 
euthyroid state is maintained through a balance be­
tween the stimulatory effect of thyrotropin-releas­
ing hormone (TRH) produced by the hypothalamus 
and the negative feedback inhibition of the thyroid 
hormones on the thyrotroph cells and on hypo- 
thalmic TRH-producing cells.
G o n a d o t r o p i c  H o r m o n e - P r o d u c in g  C e l l s
Gonadotrophs secrete both follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH) and 
occupy —10% of the anterior gland within its medial 
region (3,8). FSH and LH are glycoproteins formed 
by two noncovalently linked subunits, the previ­
ously mentioned common a-subunit and the spe­
cific (3-subunit, which confers the biological activity 
on the hormones. Gonadotropin levels are elevated 
during the first 1 to 2 years of life and rise again with 
the onset of puberty. FSH stimulates ovarian follic­
ular growth in the female and testicular growth and 
spermatogenesis in the male. In the female, LH pro­
motes ovulation and luteinization of the ovarian fol­
licle and enhances estrogen and progesterone pro­
duction by the ovary. In the male, LH supports 
interstitial (Leydig) cell function and hence the pro­
duction of testosterone by the testicle. Gonadotro­
pin secretion in the ovulating female is stimulated 
by gonadotropin-releasing hormone (GnRH) and 
both positively and negatively regulated by the go­
nadal steroids. Short-term effects of estrogens are 
suppressive on basal LH release. With longer dura­
tion of exposure to estrogens, particularly at low 
doses, gonadotropin secretion is enhanced. In 
males, testosterone has a negative feedback effect
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on hypothalamic GnRH and on the pituitary gona­
dotroph cells.
Normal Anatomy of the Neurohypophysis
The posterior pituitary lacks a blood-brain barrier 
and consists of hypothalamic-originating neuronal 
axons and terminals, specialized glial cells, and 
blood vessels. It is subdivided into three anatomical 
regions: the median eminence, the infundibular 
stem, and the neural lobe (10,11).
DIAGNOSTIC STUDIES
The evaluation of the anterior pituitary is indi­
cated in patients who present signs or symptoms 
compatible with isolated or multiple hormonal def­
icits, hyperprolactinemia, GH excess, hypercorti- 
solism, hyperthyroidism, diabetes insipidus (DI), a 
hypothalamic disorder, or with symptoms of any 
sellar or suprasellar mass. Complete examination of 
sellar and parasellar regions encompasses both neu­




As mentioned previously, the advent of radioim­
munoassay and other immunohistochemical meth­
ods have greatly enhanced our understanding of the 
function of the pituitary gland in normal and patho­
logical states (12-16). The diagnostic tests most 
commonly used to evaluate hypothalamic-pituitary 
function are listed in Table 1. In addition to recog­
nizing any hypersecretory syndromes associated 
with a pituitary adenoma, recognition of hypopitu­
itarism before any surgical endeavor is imperative; 
this may prevent complications in the perioperative 
period (see details herein). A screening neuroendo­
crine evaluation should include measurement of 
thyroid, corticosteroid, PRL, gonadotropic, and so­
matotropic hormone function.
TSH deficiency can be diagnosed by simulta­
neously measuring basal serum TSH and thyroid 
hormone levels. A low serum T4 in the presence of 
an inappropriately low TSH level suggests a central 
cause of hypothyroidism. To distinguish a hypotha­
lamic from a pituitary defect, the TSH reserve 
within the thyrotrophs may be assessed by perform­
ing a TRH test. In the intact pituitary, TSH and
T A B L E  1. D ia g n o s t ic  t e s ts  to  e va lu a te  
h y p o tha lam ic -p itu i ta ry  hypofunction
Thyroid
Serum TSH, T4, T3RU
TRH stimulation test (measure serum TSH, prolactin, GH) 
Adrenal 
Serum cortisol (8 a.m.)
Plasma ACTH (if serum cortisol low)
CRH stimulation test (measure serum ACTH)
Sex hormones 
Serum testosterone (men), estradiol (amenorrheic 
premenopausal women)
Serum LH, FSH
GnRH stimulation test (measure serum LH and FSH) 
Serum prolactin 
Growth hormone
Serum 1GF-1 and growth curve (children and adolescents) 
GH stimulation tests (GHRH, arginine, clonidine, 
propranolol, L-dopa. insulin-hypoglycemia, exercise)
TSH, thyrotropin; T4, thyroxine; T,RU, triiodothyronine resin 
uptake; TRH, thyrotropin-releasing hormone; GH, growth hor­
mone; ACTH, corticotropine; CRH, corticotropine releasing 
hormone; LH, luteinzing hormone; FSH, follicle-stimulating 
hormone; GnRH, gonadotropin-releasing hormone; 1GF-1, insu­
lin-like growth factor-1; GHRH, growth hormone-releasing hor­
mone.
PRL rise in response to TRH stimulation, and GH 
falls. TSH oversecretion, as in the context of a rare 
functional tumor, results in high circulating levels of 
both TSH and T4.
Dynamic tests are required to diagnose a state of 
ACTH deficiency because the morning cortisol is 
persistently low only when the ACTH deficiency is 
very severe. The CRH test distinguishes a hypotha­
lamic CRH deficiency from a pituitary ACTH defi­
ciency. The absence of ACTH responsiveness to 
CRH is diagnostic of a pituitary corticotroph defi­
ciency. The insulin-induced hypoglycemia and the 
glucagon test stimulate the entire hypothalamic- 
hypophyseal adrenal axis. The ACTH stimulation 
test evaluates the capacity of the adrenals to secrete 
cortisol.
Gonadotropin deficiency can be diagnosed by si­
multaneously measuring basal serum FSH and LH 
levels and gonadal steroids, estradiol in the pre­
menopausal female, and testosterone in the male. In 
the event of primary gonadal failure, the lack of 
negative feedback by the gonadal steroids on the 
hypothalamic GnRH and pituitary LH- and FSH- 
secreting cells leads to an elevation of LH and FSH. 
Low circulating gonadal steroids associated with in­
appropriately low gonadotropin levels suggest a hy­
pothalamic or pituitary disturbance. The GnRH 
stimulation test evaluates pituitary gonadotroph 
function. Lack of response of LH and FSH to 
GnRH indicates a lesion at the pituitary rather than
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the hypothalamic level. However, when the pitu­
itary gonadotroph cells has not been stimulated by 
hypothalamic GnRH for a prolonged period of time, 
repetitive GnRH stimulation may be necessary to 
elicit a secretory response.
GH levels in the basal state are often low in nor­
mal individuals. The measurement of the plasma 
IGF-1 level permits a more accurate diagnosis of a 
GH deficient state as it reflects the 24-h secretion of 
GH. Stimulatory tests to assess the somatotroph 
function include sleep and exercise studies; insulin- 
induced hypoglycemia; and administration of argi­
nine, L-dopa, clonidine, propranolol, or GHRH. 
GH hypersecretion can be assessed by measuring 
the IGF-1 level (best screening test) and by per­
forming a glucose suppression test, in which event 
the plasma glucose does not suppress below 2 |xg/L 
(see herein).
Posterior Pituitary
Central DI refers to a state of relative or absolute 
insufficient secretion of vasopressin from the pos­
terior pituitary gland (17-20). This must be differ­
entiated from renal DI in which the kidney fails to 
respond to an appropriate elevation in serum vaso­
pressin. The diagnosis of central DI may be estab­
lished by the water deprivation test. This study as­
sesses the patient’s ability to concentrate the urine 
in response to an increase in plasma osmolality. 
Both hypothyroidism and hypocortisolism may 
cause a decrease in the glomerular filtration rate 
and thus mask a state of DI. Therefore, prior to the 
test, the patient should be in a euthyroid state, and 
adrenal insufficiency, if present, should be cor­
rected. During the test, the diagnosis of DI is based 
on the development of abnormally concentrated 
plasma (osmolality >  300 mOsmol/kg) and urine 
that remains dilute (osmolality <270 mOsmol/kg). 
Also, the urine volume is not reduced to the ex­
pected degree. At the end of the water deprivation 
period (when two serial urine osmolalities vary by 
<30 mmol/kg or when 3 to 5% of the body weight 
has been lost), the administration of exogenous va­
sopressin will correct these abnormalities (in con­
trast to renal DI, in which there is resistance to 
exogenous vasopressin).
Radiographic Evaluation
Radiographic examination of the pituitary should 
provide information about the bony anatomy of the
sella and its surroundings in addition to intrasellar 
contents.
For the diagnosis and management of pituitary 
tumors, magnetic resonance imaging (MRI) has had 
a revolutionary impact. MRI is superior to com­
puted tomography (CT) because of its inherently 
greater soft tissue contrast, which allows clear vi­
sualization of the optic chiasm, optic nerves, cav­
ernous sinuses, and carotid arteries (21-28). High 
field thin section MRI appears to be the most sen­
sitive imaging method for preoperative localization 
of pituitary adenomas. On unenhanced images, fo­
cal glandular hypointensity identified on coronal 
images is the most sensitive predictor of adenoma 
location. Radiographic evaluation should consist of 
coronal, sagittal, and axial MRI, with large tumors 
usually having similar signal intensity to brain on 
Tl-weighted images. The normal pituitary gland, in- 
fundibulum, and cavernous sinuses enhance imme­
diately after administration of gadolinium-DTPA, 
allowing contrast between the enhancing normal 
glandular tissue and the low-intensity adenomas. 
Currently, a Tl-weighted image following the infu­
sion of gadolinium-diethylenetriaminepentoacetic 
acid (DTPA) is the method of choice for the delin­
eation of intrasellar pathology. Shortly after admin­
istration, the normal vascular pituitary increases in 
signal intensity (25), and a pituitary tumor contrasts 
by remaining less intense, being slower to perfuse 
with the contrast agent (Fig. 2). However, after suf­
ficient time for dye uptake into the tumor, the tumor 
increases in signal intensity accordingly. Following 
this, the normal surrounding pituitary “ washes 
out” the contrast before the tumor. Thus, the re­
verse situation prevails, and the tumor remains 
higher intensity than the surrounding gland for a 
period of time. The optimal and most consistent 
time for visualization is therefore in the early 
postinfusion period because the kinetics of dye per­
fusion and clearance may be variable among pa­
tients. MRI also offers visualization of the major 
vessels, specifically the intracavernous carotids, in­
dicating the proximity of these structures to the tu­
mor. Such visualization is especially important in 
the rare case of the presence of severely ectatic 
carotid arteries that might preclude a transnasal sur­
gical approach for risk of vascular injury.
If MRI is not available, CT may be done, per­
forming direct coronal cuts, or with coronal and 
sagittal reconstruction of axial sections through the 
sellar region. On unenhanced CT, a pituitary tumor 
usually has density slightly less than surrounding
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pituitary or cavernous sinuses. Adenomas may be 
homogeneous, contain low-density regions of ne­
crosis or cyst formation, or demonstrate intratu- 
moral hemorrhage or calcification. Such a study 
may also offer relevant information regarding the 
bony landmarks by varying the window widths and 
may reveal sellar enlargement, or sloping, thinning, 
or erosion of the sellar floor, all indicative of an 
intrasellar expansile process. In addition, the pres­
ence of calcium in some sellar or parasellar lesions 
(e.g., craniopharyngioma, meningioma) may be bet­
ter visualized on CT images, therefore providing 
information supplemental to that obtained by MRI 
(28-30).
DIAGNOSIS OF PITUITARY TUMORS AND 
THEIR TREATMENT
Currently, these tumors are classified according 
to their hormone production (if any) (31) (Table 2). 
Hormone production and secretion by an adenoma 
may be asymptomatic, but this information is none­
theless helpful in the characterization of an inciden­
tal mass on MRI. Moreover, it has recently been 
appreciated that multiple hormones may be se-
FIG. 1. Cushing’s adaptation of the transphenoidal technique. 
This 1912 drawing by the renowned medical illustrator Max 
Brodel shows the technique of transsphenoidal approach to the 
hypophysis. Note the sublabial incision adopted by Cushing at 
the time. (From Cushing H. The Weir Mitchell Lecture. Surgical 
experiences with pituitary disorders. JAMA  1914;63:1515-25).
T A B L E  2. P itu itary  a d e n o m a  typ e s  a n d  

















GH-cell PRL-cell adenoma 5.2
Acidophil stem cell adenoma 2.5
Mammosomatotroph cell adenoma 1.4
Other 4.3
Total 100.0
GH, growth homrone; PRL, prolactin; ACTH, corticotropin; 
TSH, thyrotropin; FSH, follicle-stimulating hormone; LH, 
luteinizing hormone.
From Kovacs K, Horvath E. Pathology of pituitary adenomas. 
In; Collu R, Brown GM, Van Loon GR, eds. Clinical neuroen­
docrinology. Boston: Blackwell Scientific Publications, 1988, 
with permission.
creted by some tumors (plurihormonal lesions), 
which may complicate this classification (32). A fur­
ther complicating factor lies in the definition of the 
term “ hormone production.” Classically, as cell bi­
ologists and pathologists define production as hor­
mone synthesis not necessarily associated with (or 
followed by) hormone release, the histology of the 
particular tumor may not correlate with the clinical 
endocrinological status of the patient. From a clin­
ical perspective, the true secretion of the hormone 
is important; it determines any hypersecretory en- 
docrinopathy, and thus provides a serum parameter 
for clinical diagnosis and response to treatment.
Null Cell Adenomas
Clinical Manifestations and Diagnosis
Although tumors that secrete any of the anterior 
pituitary hormones may grow to sufficient size to 
become macroadenomas, nonfunctioning adenomas 
more frequently present with symptoms of larger 
lesions, such as visual failure or hypopituitarism. 
Statistically, null cell tumors are among the most 
common kind of adenoma found in the pituitary and
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present more frequently later in life than secreting 
tumors. The classic visual triad produced by larger 
tumors is characterized by optic disc pallor, loss of 
central visual acuity, and visual field defects (bitem­
poral hemianopsia) (33).
In the endocrinological evaluation of the patient 
suspected of harboring a nonfunctioning pituitary 
tumor, an important diagnostic pitfall to be avoided 
is the misdiagnosis of a PRL-secreting tumor. 
Larger adenomas comprised of cells other than lac- 
totrophs may produce a mild to moderate hyperpro­
lactinemia from the so-called “ stalk-section effect” 
[disconnection hyperprolactinemia-stalk compres­
sion causing loss of dopaminergic inhibition to tonic 
PRL release (34-36)], which must be distinguished 
from a true prolactinoma. Under such circum­
stances, it is rare to see PRL levels >100 ng/ml, or 
at most 250 ng/ml. Consequently, large tumors (>2 
cm in size) associated with PRL levels <250 ng/ml 
(certainly those <100 ng/ml) should be suspected of 
being nonfunctional when planning management 
strategies, and one would not expect such lesions to 
physically respond to chemical reductions of serum 
PRL.
Nonsecreting pituitary adenomas may be defined 
as those that demonstrate no apparent clinical or 
biochemical abnormality indicating hormone ex­
cess, although it must be recognized that the poten­
tial for the secretion of an as yet undetectable hor­
mone or its precursor exists, or that an identified 
hormone may be synthesized in insufficient quanti­
ties to be detected by immunoperoxidase methods 
(37). Indeed, the term “ nonfunctioning” has been 
considered a misnomer by some for this reason (38). 
To be distinguished from the true nonfunctioning 
tumors are those that secrete the a-subunit, com­
mon to all of the glycoprotein hormones. In these 
cases, the a-subunit may be detected immunohisto- 
chemically in tumor specimens and biochemically 
in the blood and urine but, because it possesses no 
biological activity, it is of no endocrinological con­
sequence if secreted. However, the exclusive secre­
tion of the a-subunit may be difficult to determine if 
each of the glycoprotein hormones has not been 
independently assayed. For example, TSH-secret- 
ing tumors may secrete excessive quantities of the 
a-subunit (39).
With nonfunctioning macroadenomas, varying 
amounts of hypopituitarism may be present, pro­
duced by compression of the gland by tumor or 
from interference with blood supply leading to in­
farction of the normal functioning gland. Reversal
of hypopituitarism may be possible in some cases, 
illustrating that interruption of hypothalamic-portal 
circulation may occur without true necrosis of glan­
dular tissue (40,41).
Therapy
The two objectives of the treatment of all pitu­
itary tumors, regardless of secretory status, are (a) 
relief of signs and symptoms attributable to mass 
effect and (b) correction of endocrine abnormali­
ties—hypo- or hypersecretion of adenohypophyseal 
hormones (42). When nonsecreting tumors are con­
sidered, hormonal hypersecretory syndromes may 
not be present but it is important to realize that 
continued growth of the lesion may precipitate hy­
popituitarism.
The success of medical therapy is predicated on 
the presence of any associated oversecretion of an­
terior pituitary hormones. Thus, in cases o f non­
functioning tumors, no pharmacological therapy is 
available. The primary mode of treatment consid­
ered in these tumors should therefore be surgical, 
with other options [radiotherapy (RT) or observa­
tion] only for patients whose underlying medical 
conditions preclude surgery (43). One exception is 
the asymptomatic elderly patient with a nonsecret­
ing tumor, intact pituitary function, and no compro­
mise of the visual system. A case can be made for 
monitoring the patient with routine clinical (visual 
field) and endocrine evaluations, with serial MRI or 
CT scanning performed at least yearly. These tu­
mors may exhibit a benign course, without reaching 
symptomatic dimensions within the remaining life 
expectancy.
PRL-Secreting Adenomas
Clinical Manifestations and Diagnosis
PRL-secreting tumors are the most common kind 
of secretory pituitary tumor (44). Although these 
tumors are found pathologically at autopsy with 
equal frequency in men and women, they are clin­
ically significantly more common in women. Hyper­
prolactinemia causes galactorrhea in women and 
hypogonadism, which presents as anovulatory in­
fertility in the female and impotence in the male 
(45,46). Presumed abnormalities in pulsatile secre­
tion of GHRH and gonadotropins precipitate a rel­
ative estrogen deficiency (47,48). This hypogonadal
Neurosurgery Quarterly, Vol. 4. No. 4, 1994
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state is associated with osteoporosis in women (49) 
and both cortical and trabecular osteopenia in men
(50). In a personal series of some 392 PRL-secreting 
pituitary tumors operated on by one of the authors 
(M.H.W.), 321 (82%) were in female patients. The 
most common presenting symptom in this group 
was the development of secondary amenorrhea; 
only —50% of those with amenorrhea had associ­
ated galactorrhea. Epidem iologically, —5% of 
women with primary amenorrhea and 25% of 
women with secondary amenorrhea (other than 
those who are pregnant) harbor a PRL-secreting pi­
tuitary tumor as the cause of their clinical symp­
tomatology. Because of this readily identifiable 
symptomatology, these patients generally present 
relatively early in the course of evolution of the 
tumors; this is unfortunately not true in the male 
population. Because the primary symptomatology 
of a PRL-secreting tumor in the male is usually a 
decrease in libido well before true impotence is ob­
served, this is frequently ascribed to the “ aging pro­
cess” or “functional” causes. About two thirds of 
men with hyperprolactinem ia due to a PRL- 
secreting tumor have a low serum testosterone level
(51); this may be secondary to hyperprolactinemia 
per se or to mechanical compression of the adjacent 
normal pituitary gland. Thus, males often present at 
a more advanced age, and later in the course of their 
disease with chiasmal compression and visual com­
promise. For the same reasons, large tumors asso­
ciated with hypothyroidism and adrenal insuffi­
ciency are more common in men (51).
The diagnosis is secured by radiographic evi­
dence of a pituitary lesion with an elevation of se­
rum PRL (52). As with other pituitary adenomas, 
high-field thin-section MRI appears to be the most 
sensitive imaging method for preoperative localiza­
tion of the lesion. There exists a rough correlation 
between the size of the lesion radiographically and 
pathologically and the serum level of PRL. In addi­
tion, local invasion of the tumor into the adjacent 
venous cavernous sinuses is associated with a 
marked increase in serum PRL. The diagnosis of 
pathological prolactin excess should be based on 
serial blood measurements (53); PRL levels greater 
than five times the upper limit of normal are usually 
associated with a PRL-secreting pituitary tumor 
(54). In the endocrinological evaluation of the pa­
tient suspected of harboring a PRL-secreting tumor, 
as discussed previously, it must be appreciated that 
larger tumors of any endocrine basis may cause a 
mild to moderate hyperprolactinemia from stalk
compression, which must be distinguished from a 
true prolactinoma.
A number of reports suggest that neither tumor 
size nor PRL levels change over a number of years 
in the majority of women with microprolactinomas 
(55,56). In fact, it has been observed that few mi­
croprolactinomas progress to macroadenomas (54). 
In contrast, macroadenomas, which for reasons al­
ready described frequently present in men, may be­
have in an aggressive manner (53). They may be 
associated with invasion of the cavernous sinuses 
and diffuse invasion of the base of the skull and may 
commonly extend to the suprasellar region (57). 
Hemorrhage or cyst formation within the tumor 
may also occur.
The absolute level of elevated PRL in a diagnosed 
pituitary adenoma is of great help in determining 
subsequent management because the ability to suc­
cessfully extirpate the tumor is reduced with large 
and/or invasive lesions (discussed herein).
Indications fo r  Therapy and Goals o f  Treatment
The introduction of an effective pharmacother­
apy (bromocriptine) for PRL-secreting tumors de­
mands a central role within the overall management 
strategy for these lesions. The efficacy of bro­
mocriptine (a dopaminergic agonist) in reducing se­
rum PRL, in addition to reducing tumor size and 
inhibiting further tumor growth, is well established 
(see herein). The central considerations related to 
treating such patients is the ability of the patient to 
tolerate the medication and the realization that the 
treatment must continue for the duration of the pa­
tient’s life.
With PRL-secreting microadenomas, therapeutic 
options include medical or surgical management. In 
our series, 225 of 262 patients (86%) undergoing sur­
gery for tumors <1 cm in size had normal (<20 
ng/ml) postoperative PRL levels (ie, “ chemical 
cure” ). Operative mortality was zero and associ­
ated morbidity low. Strong consideration should be 
given to surgical intervention in patients harboring 
smaller tumors without significant hyperprolactin­
emia.
Very high levels of serum PRL (>1000 ng/ml) are 
usually indicative of an invasive tumor, an impor­
tant consideration when contemplating the likeli­
hood of surgical cure. For larger tumors, surgical 
chemical cures (serum PRL <20 ng/ml postopera­
tively) are much less frequent. Those tumors asso­
ciated with PRL levels >200 ng/ml recur in >50% of
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cases following surgery alone (45); recurrence of 
hyperprolactinemia after surgery for macroade­
nomas (with PRL levels >250 ng/ml) is >70%  
(38,45). In our personal series, only 63 of 130 (49%) 
of those patients with tumors >1 cm achieved 
chemical cure. Although no medical therapy results 
in cure of a PRL-secreting macroadenoma, only a 
minority of these patients remain free of their dis­
ease following surgery alone. Bromocriptine should 
therefore be considered as initial therapy for those 
patients in whom surgical resection resulting in 
chemical cure is deemed unlikely (58). It is our 
present practice to place all patients with large or 
invasive pituitary tumors with endocrinologically 
documented PRL secretion on a trial of bromocrip­
tine initially and to monitor clinical status and ra­
diographic appearance accordingly. All solid pri­
mary PRL-secreting tumors should respond to the 
medication, both clinically by a reduction in tumor 
size and by a reduction in PRL level. However, 
primary cystic  tumors are much less likely to re­
spond to pharmacotherapy (59).
The goals of treatment of prolactinomas include 
(a) reduction of the tumor mass, (b) correction of 
the hyperprolactinemic state, and (c) preservation 
of anterior pituitary function (45). The tenet of ther­
apy should be absolute normalization of PRL levels 
because a prolonged hyperprolactinemic state may 
be associated with significant osteoporosis and in­
fertility. Surgical resection of these lesions is indi­
cated in those patients intolerant of the side effects 
of the medication, unable to afford the cost of the 
medication for a prolonged period of time, or in 
whom sustained tumor reduction is not effected. 
Subsequent to surgery, if hyperprolactinemia is per­
sistent to some extent, the patient may be able to 
tolerate markedly reduced doses of bromocriptine 
to effect long-term control or one would consider 
the use of postoperative RT to bring the residual 
tumor under control.
After RT for prolactinomas, PRL levels fall 
slowly over many years, but rarely reach normal 
(45). Thus, these patients may benefit from adju­
vant medical therapy with bromocriptine.
Pharmacotherapy with Dopaminergic Analogues
Physiology. Bromocriptine is a dopamine agonist 
that suppresses PRL production and release by the 
stimulation of dopamine receptors. This orally ac­
tive dopamine agonist is a semisynthetic ergot alka­
loid that was specifically developed as an inhibitor
of PRL secretion. It directly stimulates neuronal 
and pituitary cell membrane dopamine receptors 
(60). A single dose of 2.5 mg results in suppression 
of serum PRL for =sl4 h (61). The biological effect, 
however, may persist >24 h in some patients (44).
Dose and m ode o f  administration. Currently, 
bromocriptine is the only dopaminergic analogue 
that has been FDA-approved for the clinical treat­
ment of hyperprolactinemia (45). It has proven safe 
and effective in 15 years of widespread use in the 
treatment of prolactinomas since its approval in 
1978 (44). To avoid the occurrence of side effects 
when initiating therapy, a low dose of 1.25 mg 
should be administered at bedtime. Gradual in­
creases in increments of 1.25 mg should be made 
every 3 to 4 days until the desired effect is reached 
(1). Most patients respond satisfactorily to a dose of 
2.5 mg t.i.d. The medication should be taken with 
meals (44). In some patients with large tumors 
whose size does not decrease or whose PRL level is 
not suppressed by >80% of pretreatment levels 
with the above dose, much larger doses are re­
quired, up to 15 to 20 mg daily (44,45). However, in 
certain cases, the dose may be decreased after 
achievement of adequate suppression (44). In pa­
tients with macroprolactinomas treated initially 
with bromocriptine, if reduction in tumor size has 
not occurred *s3 months, it is unlikely to occur, and 
medical therapy should be abandoned (45). In the 
bromocriptine-treated patient who responds but 
fails to normalize serum PRL and does not achieve 
restoration of gonadal function, a combined surgical 
and medical approach should be considered. After 
the surgical procedure, the hyperprolactinemia is 
often more responsive to medical therapy, requiring 
lower doses for control of PRL (45). Dopamine ag­
onist therapy must be given chronically. In most 
patients, withdrawal of the drug results in a return 
of hyperprolactinemia and reexpansion of the tumor 
(62,63). Occasionally, patients with a microade­
noma or an unidentifiable tumor do not have recur­
rence after discontinuation of therapy. In a patient 
with a microadenoma, bromocriptine can be discon­
tinued every 2 years on a trial basis to determine the 
need for continued therapy (44,49).
Efficacy. Following adequate bromocriptine ther­
apy, the PRL levels are usually lowered by >80% 
or normalized (45). The PRL-reducing response to 
therapy in patients with microadenomas and with 
macroadenomas is similar, with the exception that 
in the latter group, the time required for effective 
lowering of PRL is usually longer (44). In addition,
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in >80% of patients, bromocriptine and other do­
pamine agonists are effective in reversing visual ab­
normalities and restoring gonadal and anterior pitu­
itary functions (45,54). Most female patients begin 
menstruation =£6 months of initiating therapy. The 
restoration of fertility in women with bromocriptine 
has been well documented (64).
In addition to reducing PRL secretion, bro­
mocriptine is effective in decreasing tumor size (59, 
65,66). The size reduction of the tumor may occur 
very rapidly, within days of initiation of therapy, 
and achieve dramatic decompression of the optic 
chiasm and resolution of headaches and other signs 
and symptoms of raised intracranial pressure (45). 
Some tumors are very responsive to bromocriptine 
and shrink >80% in ®;6 weeks of initiation of ther­
apy (45). Although the vast majority of patients 
have a satisfactory biochemical and clinical re­
sponse to medical therapy, there have been isolated 
case reports of lack of response or progression of 
disease during bromocriptine therapy (67-69). 
C lose monitoring is therefore mandatory. In 
women, once hyperprolactinemia has been cor­
rected and the menstrual cycle normalized, fertility 
is usually reestablished and the pregnancy rates are 
the same as those of normal women in the same age 
group (70,71). Although it is tempting to intuitively 
suggest that pretreatment with bromocriptine may 
shrink the tumor and facilitate surgical resection, no 
study has yet reported higher surgical cure rates 
after such preoperative treatment with bromocrip­
tine (72,73).
Histological changes. Bromocriptine therapy of 
human prolactinomas for a period of 2 weeks has 
been shown to induce cell shrinkage and degenera­
tive, necrotic, and fibrotic changes in the tumor; the 
secretory granules within a cell increase in number 
but not in volume (74). Others have demonstrated 
that the cytoplasmic and nuclear volumes are re­
duced. In the cytoplasm, the amount of rough en­
doplasmic reticulum and size of the Golgi apparatus 
are markedly reduced, and the cell changes from 
appearing highly active to quiescent. These changes 
are reversed after bromocriptine withdrawal (45).
M edical management and pregnancy. Pregnant 
women harboring microprolactinomas rarely de­
velop complications related to tumor expansion; the 
reported risk ranges from only <0.5 to 1% (44,45). 
However, in pregnant women with macroprolacti­
nomas, the situation is quite different; the risk of 
developing symptoms related to tumor enlargement 
such as headache, visual field disturbances, and
ophthalmoplegia is —15%, and that of developing 
asymptomatic tumor enlargement 9% (75). These 
complications appear to occur with equal frequency 
during all trimesters (70). Therefore, measures to 
reduce tumor size such as surgery and radiation are 
recommended prior to conception in female pa­
tients harboring macroadenomas who desire to be­
come pregnant. In the event of significant tumor 
enlargement during pregnancy, bromocriptine has 
been shown to be safe and effective (76-78). Its 
administration during pregnancy has not increased 
the risk of congenital anomalies, spontaneous abor­
tion, or multiple births (79,80). Motor and psycho­
logical development of children born to women 
treated with bromocriptine during pregnancy were 
normal (80).
If a pregnancy is planned by a patient on bro­
mocriptine therapy, a coordinated schedule of fol­
low-up must be observed by the patient, endocri­
nologist, and neurosurgeon. It is currently recom­
mended that a woman with a prolactinom a, 
regardless of tumor size, who wishes to become 
pregnant while on bromocriptine therapy use me­
chanical contraceptive precautions for 3 months. 
During this period, she should undergo complete 
endocrine, neuroradiologic, and neuroophthalmo- 
logic evaluations. After achieving three regular 
menstrual cycles, she should discontinue the con­
traceptive precautions. Pregnancy should be sus­
pected when the menses are 2 days overdue, and at 
that time a serum [3-human chorionic gonadotropin 
level should be measured. Once pregnancy is con­
firmed, the bromocriptine should be immediately 
discontinued. The patient would then be followed 
closely for signs and symptoms of tumor expansion. 
Should visual field abnormalities develop, bro­
mocriptine therapy would be indicated as the clini­
cal situation warrants (44). After termination of 
pregnancy, headaches and visual field defects ac­
quired due to tumor expansion resolve as the tumor 
becomes smaller in all cases.
Side e ffec ts .  Significant side effects o f bro­
mocriptine include malaise, nausea, vomiting, and 
postural hypotension. Less commonly, headache, 
abdominal cramps, constipation, nasal congestion, 
and depression have been described. Hallucinations 
have been reported in 1.3% of patients (81) and, 
rarely, cold-induced vasospasm most pronounced 
in the digits may occur (82). A rare complication in 
patients with large prolactinomas is the develop­
ment of a cerebrospinal (CSF) fluid leak during 
treatment, caused by shrinkage of the tumor (49). In
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women, galactorrhea may persist even though PRL 
is lowered to the normal range (83). It has been 
reported that if bromocriptine is given for months, 
the tumor may become fibrous in consistency, 
which may cause difficulty with surgical resection 
(65). This has not been our personal experience.
GH-Secreting Adenomas
Acromegaly  and gigantism  are the result of over­
secretion of GH into the somatic circulation. Col­
lectively, they are second in frequency to hyperpro­
lactinemia as pituitary hypersecretory syndromes. 
They are almost always caused by a somatotroph 
(i.e ., GH-secreting) adenoma o f the pituitary 
{>99%  of cases) as opposed to somatotroph hyper­
plasia from excess secretion of ectopic GHRH (82). 
The majority of these pituitary tumors exhibit a 
moderate growth rate and often present as mac­
roadenomas with extrasellar extension and focal de­
struction (84,85) [85 to 90% of patients present with 
macroadenomas and 10 to 15% with microade­
nomas (82)].
Younger patients with acromegaly often harbor 
larger and more rapidly growing tumors (86). Ac­
romegalic tumors may contain and also secrete PRL 
or the a-subunit (common to all the glycoprotein 
adenohypophyseal hormones) and, rarely, TSH in 
addition to GH (84). Most patients with large tu­
mors have mixed GH and PRL hypersecretion (87), 
which results in concomitant hyperprolactinemia in 
20 to 40% of patients (84,86). PRL is most often 
secreted from a tumor containing a mixed popula­
tion of somatotroph and lactotroph cells (an acido­
philic stem cell tumor) but occasionally from a bi­
potential mammosomatotroph adenoma (85). In pa­
tients harboring mammosomatotroph adenomas, 
the two hormones by definition are present within 
the same cell and/or the same secretory granule and 
are usually secreted in a similar dynamic pattern 
(86).
The total amount of GH secreted in a 24-h period 
is variable among patients and depends on cell ac­
tivity but roughly correlates with the size of the 
tumor (88). GH oversecretion results in elevated 
plasma IGF-1 levels (84) that are fairly stable and 
reflect the integrated, pulsatile 24-h secretion of 
GH. As GH levels increase, IGF-1 rises linearly 
until GH reaches —20 (xg/L, after which the IGF-1 
level plateaus. As a corollary, to achieve any mea­
sure of successful treatment, GH must decrease to 
a level <20 |xg/L for IGF-1 levels to drop or clinical
improvement to occur (82). However, there is a 
poor correlation between plasma GH levels and 
clinical manifestations of acromegaly, presumably 
because of variable responsiveness of peripheral 
tissues to GH excess (84).
Clinical Manifestations and Diagnosis
The clinical manifestations of excess secretion of 
GH are dependent on the age of the patient. If the 
excess secretion occurs in childhood or adoles­
cence before the epiphyses of long bones have 
fused, the result is gigantism. Such individuals may 
attain great height (often >7 ft) if the disease pro­
gresses unchecked. After fusion of the epiphyses, 
excess GH produces the syndrome of acromegaly  
in adults, with soft tissue and bony enlargement in 
characteristic locations. Clinical manifestations of 
these soft tissue changes include coarsening of fa­
cial features, laryngeal enlargement, goiter, thick 
heel pads, acanthosis nigricans, cardiomegaly, and 
hepatomegaly. Bony changes are extensive, pro­
ducing facial prognathism, enlargement of the man­
dible with increased spacing between the teeth, and 
bony enlargements of hands and feet. Soft tissue 
and bony changes may produce compressive neu­
ropathies and arthropathies. Metabolic manifesta­
tions include hypertension, diabetes mellitus, and 
goiter, and, commonly, hyperhidrosis. Deficiencies 
in ACTH and TSH are found in >10 to 20% of 
patients. Hypogonadism occurs in 30 to 40% of pa­
tients but may be attributable to associated hyper­
prolactinemia (84) and may result in osteoporosis. 
Acromegaly affects men and women with approxi­
mately equal frequency.
The diagnosis is made by assessing GH secretion. 
A basal fasting GH level >10 ng/ml is present in 
90% of acromegalics. However, because GH is se­
creted in several peaks throughout the day, a single 
fasting level may fail to demonstrate an elevated 
level in some patients. The suspected diagnosis is 
therefore confirmed by the glucose suppression 
test. In the acromegalic, an oral administration of 
100 g of glucose fails to suppress the serum GH 
level to <2 |xg/L at 60 min. The measurement of 
serum IGF-1 levels are elevated in acromegalics 
and prove to be a more reliable measure of the dis­
ease and its response to treatment. Radiographic 
imaging (MRI and/or CT) demonstrates the pres­
ence of a pituitary adenoma in >90% of patients 
with endocrinologically documented acromegaly.
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Excess secretion of GH should be considered a 
malignant endocrinopathy that may result in life- 
threatening medical complications and thus should 
be treated aggressively once diagnosed. The goals 
of therapy in management of a GH-secreting pitu­
itary adenoma include (a) resolution of tumor mass 
effect, (b) restoration of normal GH physiology (ab­
solute normalization of GH and IGF-1 levels), and 
(c) replacement of any associated hormone defi­
ciencies. Many authors now believe that criteria for 
successful therapy (chemical cure) include a 24-h 
integrated GH concentration =£2.5 (xg/L together 
with normalization of the circulating IGF-1 level 
(85,89).
Microadenomas
In the patient harboring a GH-secreting microad­
enoma who is sufficiently medically stable to un­
dergo surgery, surgical resection should be consid­
ered the optimal first line of management. The 
transsphenoidal approach is certainly the approach 
of choice to these lesions, but the transnasal dissec­
tion in the acromegalic patient with associated soft 
tissue and bony changes may present an added chal­
lenge for the surgeon. However, in our personal 
experience, this has never been a limiting factor in 
the use of the transsphenoidal approach. Such tu­
mors may be cured by chemical criteria in the ma­
jority of cases. In our personal series, 74% of pa­
tients with microadenomas undergoing transsphe­
noidal resection achieved normal postoperative 
IGF-1 levels, and 76% achieved postoperative GH 
levels <5 (xg/L. Postoperative persistent elevation 
of GH or IGF-1 levels are an indication for pharma­
cotherapy or RT (discussed herein).
M acroadenomas
The patient harboring a GH-secreting macroade­
noma poses a more difficult management dilemma. 
Certainly the likelihood of cure in these tumors is 
low in cases of large tumors with frank cavernous 
sinus invasion, and pharmacotherapy or RT should 
be considered integral components in the overall 
management plan. In these cases, initial pharmaco­
therapy may be indicated; however, surgical resec­
tion may be helpful in decreasing tumor load to ef­
Indications fo r  Therapy and Goals o f  Treatment fect an absolute normalization of IGF-1 levels by 
pharmacotherapy (90).
Pharmacotherapy
Pharmacotherapy should be considered in (a) pa­
tients in whom surgery is contraindicated; (b) pa­
tients whose GH and IGF-1 levels are still elevated 
after surgery, as an alternative for RT at this stage; 
or (c) patients with elevated GH and IGF-1 levels 
after surgery and RT (82). Medical therapy may be 
administered in conjunction with RT to provide in­
terim GH suppression while awaiting the beneficial 
effects of the radiation.
Somatostatin Analogues
Physiology. Native somatostatin is believed to 
control GH secretion by suppression of GH release 
from the pituitary gland and GHRH from the hypo­
thalamus (91). There is at present only one FDA- 
approved analogue appropriate for clinical use— 
octreotide (Sandostatin, Sandoz, East Hanover, 
NJ, U.S.A.; previously designated SMS 201-995) 
(92). Octreotide contains the active sequence of so­
matostatin. Octreotide appears to control GH se­
cretion by suppression of GH release from the pi­
tuitary gland and by suppression of GHRH from the 
hypothalamus (91). In comparison to the native hor­
mone, it has enhanced binding affinity to the so­
matostatin receptor and a prolonged half-life of 110 
min after s.c. injection of a 50- to 100-(a.g dose, pro­
viding an overall duration of effect of 6 to 8 h (93). 
A single injection of octreotide produces a decrease 
in GH levels within 30 to 60 min, with maximum 
suppression of GH levels occurring in 2 to 4 h (94). 
Analogues currently under investigation have 
greater biologic potency than octreotide and are 
more specific for the pituitary gland (85).
Tumor somatostatin receptor status. Large num­
bers of specific somatostatin-binding sites in human 
GH-secreting pituitary adenomas have been dem­
onstrated (95-97). There appears to be heterogene­
ity with regard to the number of somatostatin re­
ceptors between tumors and in their distribution 
within a particular tumor. Most tumors contain so­
matostatin receptors in densities comparable to 
those in normal somatotrophs (97) and respond nor­
mally to somatostatin (98). However, 10 to 30% of 
GH-secreting tumors have reduced numbers of so­
matostatin receptors; patients with such tumors ex-
Neurosurgery Quarterly, Vol. 4, No. 4, 1994
M A N A G E M E N T OF P1TUITAR Y A D E N O M A S 259
hibit diminished in vivo responses to octreotide 
(97).
Dose and mode o f  administration. The usual ini­
tial dose is 100 |xg s.c. every 8 h, and this dose 
should be increased until adequate suppression is 
achieved. In acromegalics treated with octreotide, a 
close correlation has been found between the mean 
24-h GH levels and IGF-1 levels before and during 
therapy (99-102). Therefore, regular IGF-1 mea­
surements on an outpatient basis enable optimiza­
tion of the daily dose and number of octreotide in­
jec tio n s needed  for each individual patient 
(100,102). The majority of patients achieve control 
with 300 to 600 |xg per day (94). In a recent national 
survey, doses of 750 |i.g per day resulted in in­
creased frequency of tumor shrinkage without add­
ing any biochemical or clinical benefit (103). Over a 
6-month period, the size of the pituitary tumor was 
reduced in 34% of patients receiving this latter dose 
versus 17% of patients receiving 300 |xg per day. At 
present, the maximum recommended dosage is 1500 
jxg per day (85). As many as 50% of patients can be 
maintained on a twice daily regimen (104), but some 
patients may achieve better control by administer­
ing the same daily dose every 6 h instead (85). In 
this regard, continuous s.c. pump infusion of 100 to 
600 |xg per day has been shown to provide superior 
and more stable suppression of mean 24-h GH lev­
els (105).
Efficacy. Seventy-five to 90% of acromegalic pa­
tients experience biochemical, clinical, and meta­
bolic improvement with octreotide therapy. Clinical 
improvement may be heralded by disappearance or 
amelioration of excessive sweating, headaches, par­
esthesia, soft tissue swelling, and joint pain and im­
provement of nerve entrapment symptoms, to­
gether with a general sense of well-being (85,103). 
Immediate and prolonged relief of headaches is ex­
perienced in some patients with acromegaly, gener­
ally those with evidence of suprasellar tumor exten­
sion (106). Visual field improvement has been noted 
in many without demonstrable change in tumor size 
(described herein) (85). In some patients, dose- and 
time-related symptoms indicative of drug depen­
dency occur (107) and may be mediated by the bind­
ing of octreotide to the opioid |x-receptor (85).
Effective decreases of GH and IGF-1 levels occur 
in 30 to 53% and in 40 to 68% of patients, respec­
tively, according to various studies (85,93,94,103, 
108,109). In most patients, IGF-1 levels fall =£l 
week of the start of treatment and tend to normalize 
in 37 to 81% of cases with continued therapy
(103,104,110-112). GH and IGF-1 levels have been 
shown to continue to decrease with long-term treat­
ment of 1.5 to 2 years when compared to levels at 6 
to 12 months (113). Long-term responsiveness can 
be predicted by the acute GH-suppression effect of 
a single test injection of 50 |xg of octreotide. The 
mean hourly GH level from 2 to 6 h after drug in­
jection or any time during s.c. infusion are also use­
ful predictors of efficacy (85). Plasma PRL levels in 
patients with mixed GH-PRL-containing tumors 
have been shown to be suppressed by octreotide in 
about one half of cases (113). Elevated concentra­
tions of the a-subunit, which can be found in —35% 
of acromegalic patients (115), respond to octreotide 
in a similar fashion to the changes in GH level (94).
Preoperative treatment with octreotide causes 
the tumor to become soft in consistency and to ex­
hibit a grayish-red color at surgery (116). Several 
neurosurgical groups have concluded that pretreat­
ment with octreotide with softening of the adenoma 
has facilitated surgical resection (116,117). Long­
term octreotide therapy produces a slight decrease 
in pituitary tumor size in —20 to 50% of acromegalic 
patients (100,101,103,118). Complete tumor shrink­
age has been reported in isolated cases (119). Tu­
mor size may increase soon after stopping the drug
(120), but in occasional patients, a period off the 
drug may subsequently permit comparable control 
to be achieved with a lower dose. This phenomenon 
is possibly explained by a reversal of somatostatin 
receptor down-regulation (85).
H istological changes. Shrinkage of adenomas 
during octreotide therapy might reflect a decrease 
in the size of individual tumor cells (94). Electron 
microscopy of adenomas pretreated with octreotide 
revealed small necrotic cells and a greater number 
of macrophages; normal pituitary cells showed an 
accumulation of lipoprotein and secretory granules
(121). These morphological findings were primarily 
consistent with chronic suppression of GH release.
Side effects. Though the drug is generally well 
tolerated, several side effects have been reported. 
Within the first few days of administration, a tran­
sient decrease in gastrointestinal motility and 
slowed absorption occur in most patients. The pa­
tient may experience transient abdominal pains and 
bloating. Steatorrhea, presumably due to a reduc­
tion in pancreatic exocrine secretion (104), occurs 
less frequently but may persist with long-term ther­
apy. Treatment with pancreatic enzymes, if neces­
sary, is usually effective (82). Nutritional deficiency 
has not been reported. Toxic hepatitis has occurred
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very infrequently. Inhibition of insulin secretion 
can lead to hyperglycemia, though the concomitant 
improvement in glucose tolerance as a consequence 
of a decrease in GH secretion is generally sufficient 
to prevent this. Though somatostatin inhibits TSH 
secretion, hypothyroidism has not been reported 
during long-term octreotide therapy (100,101,110). 
The side effect of greatest concern is cholelithiasis 
due to suppression of cholecystokinin secretion and 
a resulting decrease in bile flow. Because the inci­
dence of gallstone formation in patients on long­
term octreotide is 40 to 50% (89,122), all patients 
should be regularly screened for gallstone develop­
ment during treatment (104). No allergic reactions 
related to octreotide have been reported, although 
antibodies to octreotide have been detected in one 
patient (87). Tachyphylaxis or desensitization have 
not been observed during long-term treatment (94). 
Although the injections are often painful, this may 
be minimized by slow injection of the drug (82).
Dopaminergic Analogues
Physiology. Dopamine agonists stimulate GH se­
cretion from normal subjects through a CNS- 
mediated mechanism that increases GHRH secre­
tion (123) and possibly through the regulation of 
somatostatin secretion (85). In contrast, in acrome­
galic patients, the agonists suppress  GH secretion 
in at least half of cases (124) through a PRL- 
dependent D2 receptor mechanism (53). Dopamine 
agonists are primarily effective in GH-secreting tu­
mors that also secrete PRL (85). Unfortunately, 
many acromegalic tumors contain few or no D2 re­
ceptors, which is reflected by a poor clinical re­
sponse to these drugs.
Dose and mode o f  administration. All the cur­
rently available agents are members of the ergoline 
family of compounds. As stated previously, bro­
mocriptine (Parlodel, Sandoz, East Hanover, NJ, 
U .S.A .) is available for use in the United States. 
Initiation of bromocriptine therapy is as described 
in the previous section for use in PRL-secreting ad­
enomas. Up to 20 to 30 mg bromocriptine per day 
has been used to obtain maximum benefit, a dose 
that has been frequently associated with side effects 
(82,85).
Therapeutic effects. Amelioration of signs and 
symptoms of GH excess occur in 70% of treated 
acromegalic patients although GH levels are re­
duced to «10  ng/ml in only 50% and to s£5 ng/ml in 
only 20% of these patients (85). Only 8% of patients
achieve normal IGF-1 levels, which is the only re­
liable parameter for assessing overall normalcy of 
pulsatile GH secretion (82). Less favorable results 
are seen with larger tumors and if initial GH levels 
are >50 ng/ml (53). Tumor shrinkage is uncommon, 
occurring in only 10 to 15% of patients (85,125).
The only known factor predicting responsiveness 
to dopaminergic agonists is coexistence of PRL hy­
persecretion. Even in such patients, it is not un­
usual to achieve total suppression of prolactin se­
cretion with only partial or no suppression of GH 
(85). A single test dose of bromocriptine (2.5 mg po) 
followed by hourly plasma GH levels for 4 to 6 h 
may be used to assess therapeutic efficacy. Caution 
should be observed during this test because side 
effects may occur following administration of this 
dose.
Histological changes. At a morphological level, 
bromocriptine produces almost no change in human 
GH-secreting adenomas, except for an increase in 
the stromal tissue volume with occasional occur­
rence of vacuolation and single-cell necrosis (74).
Side effects. Commonly occurring side effects of 
bromocriptine therapy have been discussed previ­
ously in the PRL-secreting adenoma section.
Combined Use o f  Bromocriptine and Octreotide
Few patients who do not respond to either oc­
treotide or to bromocriptine alone respond to the 
combination of octreotide and bromocriptine (94, 
113,126,127).
ACTH-Secreting Adenomas
Clinical Manifestations and Diagnosis
Cushing’s disease is the result of hypersecretion 
of ACTH by the pituitary. ACTH-secreting tumors 
exist in >90% of such patients, with diffuse corti- 
cotrope hyperplasia from hypersecretion of CRH as 
the cause of excess ACTH secretion in the remain­
der. The disease affects women ~8  times more fre­
quently than men.
Clinical manifestations of the disease include (a) 
those due to glucocorticoid excess: central obesity, 
“ moon” facies, dorsocervical and supraclavicular 
fat pads, proximal muscle wasting, thin skin with 
ecchymoses and violaceous striae, cataracts, osteo­
porosis, amenorrhea, diabetes mellitus, hyperten­
sion, hypercalcuria (due to bone resorption),
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growth retardation in children, and immunosup­
pression with fungal infections; and (b) those due to 
peripheral androgen excess: hirsutism and acne (vi­
rilization is unusual). Peripheral androgen and cor­
tisol excess may cause hypogonadism by increasing 
the negative feedback to the pituitary and hypothal­
amus.
The diagnosis of Cushing’s disease is confirmed 
by (a) increased basal plasma cortisol levels and 
urinary excretion of free cortisol (two consecutive 
basal 24-h urine collections); (b) inappropriately 
high plasm ACTH concentrations (i.e., within or 
above the normal range); and (c) relative resistance 
to glucocorticoid negative feedback-inhibition. This 
relative resistance is shown by (a) low-dose dexa- 
methasone suppression test (overnight 1 mg dexa- 
methasone screening test or the standard 2-day test 
of 0.5 mg q6h for 2 days) that distinguishes Cush­
ing’s syndrome of any cause from normal cortisol 
secretion (plasma cortisol and ACTH levels should 
be suppressed to <140 nmol/L and 4.4 pmol/L, re­
spectively); and (b) high-dose dexamethasone sup­
pression test (overnight 8 mg dexamethasone test or 
standard 2-day test of 2 mg q6h for 2 days). Any 
degree of reproducible suppression that is greater 
than the daily variation and assay error is indicative 
of Cushing’s disease. ACTH secretion is already 
suppressed in patients with either adrenal tumors or 
ectopic ACTH syndrome.
Cushing’s disease may also be differentiated from 
ectopic ACTH secretion by performing (a) the CRH 
test (in Cushing’s disease, ACTH secretion re­
sponds to CRH) and (b) a metyrapone test, in which 
case there is an increase in plasma ACTH level and 
11-deoxycortisol level (>5 |xg/dl) in the setting of an 
undetectable plasma cortisol concentration. The ec­
topic ACTH-producing tumor does not respond to 
CRH and demonstrates a subnormal response to 
metyrapone. Petrosal venous sampling may be in­
dicated to localize a pituitary ACTH-secreting ade­
noma undetected by CT or MRI studies. With this 
technique, a pituitary ACTH-producing tumor is 
identified when a gradient is noted between the 
petrosal vein and the peripheral blood (128).
Therapy
Fortunately, most patients with Cushing’s dis­
ease harbor microadenomas that lend themselves to 
complete surgical resection (129). Our experience 
with these microadenomas has been gratifying; in 
those patients with Cushing’s disease harboring mi­
croadenomas, the series has demonstrated a 91% 
chemical cure rate. On the other hand, patients with 
Cushing’s disease who harbor macroadenomas 
present a serious problem. These tumors are fre­
quently invasive into adjacent dura and bone and 
consequently defy chemical cure by surgical means 
alone. If elevated ACTH levels persist after radical 
surgical resection and no residual intrasellar tumor 
is defined by imaging studies, we are currently ex­
ploring stereotactic radiosurgery as a method to 
eradicate residual sellar and parasellar invasion 
while sparing adjacent structures (as opposed to 
standard external beam RT; description herein).
Adults respond to conventional external beam 
RT in only 40% of cases and do so over a period of 
12 to 18 months (128). For the 60% of patients who 
do not respond, medical treatment is indicated. In 
this latter group, RT has the beneficial effect of pro­
tecting the patient from developing Nelson’s syn­
drome at a later date. The first line of medical ther­
apy consists of an adrenolytic agent, mitotane, for a 
period of 6 to 9 months, with the goal of suppressing 
cortisol secretion. Mitotane is initiated at a dose of
0.5 g per day and increased to 4 g per day, half the 
dose being administered at bedtime to alleviate side 
effects. D exam ethasone replacem ent therapy  
should be started to avoid adrenal insufficiency. 
Mineralocorticoid replacement is usually not re­
quired. Side effects include nausea, vomiting, rash, 
leukopenia, ataxia, gynecomastia, and arthralgias. 
Twenty percent of patients do not respond to mito­
tane and require therapy with an adrenal enzyme 
inhibitor that usually controls the disease. These 
agents include aminoglutethimide at a dose of 250 
mg b.i.d. or t.i.d. This drug increases dexametha­
sone metabolism, and therefore replacement with 
hydrocortisone is required. Aldosterone production 
will be inhibited, and replacement therapy with a 
mineralocorticoid such as fludrocortisone is neces­
sary. Side effects of this medication include a tran­
sient pruritic rash, hypothyroidism, goiter, and som­
nolence when dosages >1 g per day are administered. 
The second adrenal enzyme inhibitor available is 
metyrapone, which only partially decreases serum 
cortisol levels. This medication is indicated when 
cortisol elevation is mild or following RT while 
waiting for full clinical effect. The dose required is 
~ 2  to 4 g per day in divided doses. Side effects 
include nausea, headaches, sedation, and rash. Ke- 
toconazole is a third enzyme inhibitor that also in­
hibits ACTH. The usual dose necessary is 200 to 
400 mg po b.i.d. or t.i.d. Side effects include nau­
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sea, vomiting, headache, impotence, gynecomastia, 
and reversible hepatotoxicity. Metapyrone and ami- 
noglutethimide are often used in combination at 
lower dosages to reduce side effects.
In those patients in whom surgical therapy, RT, 
or medical therapy has been unsuccessful, adrenal­
ectomy is indicated (128).
Other Secreting Pituitary Adenomas
Tumors of the pituitary causing oversecretion of 
TSH or gonadotrophs have been described but are 
much less common than those previously men­
tioned (Table 2). In patients harboring TSH- 
secreting adenomas, the TSH level is <10 mU/L in 
one third of cases (4). These cases can be differen­
tiated from other sources of hyperthyroidism by the 
presence of an a-subunit:TSH ratio >1. Gonado­
troph adenomas usually present in middle-aged men 
with normal sexual function, headache, and visual 
changes. Hypersecretion of intact FSH is the most 
common anomaly; inappropriately normal LH lev­
els in the presence of a low testosterone value may 
also occur. This LH hormone is biologically inac­
tive. Hypersecretion of intact LH by some tumors 
causes elevation of serum testosterone levels. Ele­
vated serum a-subunit concentrations may also be 
detected. In —50% of patients with gonadotropic 
tumors, administration of exogenous TRH pro­
vokes inappropriate elevations of serum LH and 
FSH. The TRH test may therefore be of diagnostic 
value.
The treatment of these lesions is surgical, with 
RT reserved for those patients who are not surgical 
candidates or in whom total resection is not 
achieved. Reports of octreotide lowering serum 
TSH concentration in patients harboring TSH- 
secreting tumors have been described. If hyperthy­
roidism persists despite surgery and RT, treatment 
with antithyroid drugs may be necessary.
SURGERY FOR PITUITARY ADENOMAS 
Historical Background
Although Marie correctly ascribed the clinical 
syndrome of acromegaly to the presence of a pitu­
itary adenoma as early as 1889, it was not until 1893 
that Caton and Paul recorded the first attempt at 
surgical resection of a pituitary tumor (130). Their 
attempt at utilization of a two-stage lateral subtem­
poral procedure as suggested by Sir Victor Horsley
(131) was unsuccessful; the patient died before this 
effort could be completed. Subsequently, Horsley 
himself, utilizing a lateral middle fossa approach, 
reported successful surgical resections in 8 of 10 
pituitary tumors operated on between 1904 and 
1906. Krause in 1905 introduced the frontal trans- 
cranial approach to the sella; this technique has pro­
vided the basis for a majority of subsequent varia­
tions of transcranial approaches (132).
These basic approaches were modified and aug­
mented by a number of the giants of neurosurgical 
development in the early part of the twentieth cen­
tury. Modifications of these approaches described 
by Frazier, Dandy, Heuer, and Cushing, primarily 
favored the direct intradural approach to the sella 
and its contents. With the profound influence of 
these individuals, it could be recognized by the 
1930s that most neurosurgical approaches to the pi­
tuitary centered about a transcranial intradural 
technique even though some neurosurgeons contin­
ued to utilize an extradural approach. Heuer (133) 
advocated a lateral anterior fossa approach using 
the landmarks provided by the sphenoid ridge. This 
approach seemed to be the shortest distance be­
tween the inner table of the skull and the sella. Fra­
zier (134), on the other hand, described a frontal 
transcranial approach beginning at the midpoint be­
tween the midline and the lateral sphenoid wing. 
Cushing, finally, preferred a direct midline ap­
proach (135). The dominant neurosurgical teaching 
during the 1930s and 1940s continued to focus on a 
transcranial approach to the pituitary; this tech­
nique was further refined and promulgated by the 
extensive experiences of Olivecrona (136) and Ray 
(137) during the 1950s. These major figures of inter­
national neurosurgery promulgated the utilization 
of a transfrontal intradural approach to the pituitary 
during the course of developing an extensive expe­
rience with hypophyseal ablation that had become a 
major adjunct in the management of metastatic 
breast and prostate carcinoma as well as diabetic 
retinopathy. Ray personally performed >1,000 pro­
cedures on the pituitary and emphasized the need 
for a properly placed low bone flap to minimize 
brain retraction in gaining access to the sella and 
parasellar areas.
The earliest attempts at transcranial approaches 
to the pituitary at the turn of the century and shortly 
thereafter, however, resulted in a mortality that was 
generally considered prohibitive. Horsley, in the 
small series of 10 cases referred to previously, ex­
perienced a 20% mortality, certainly unacceptable
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by modern standards but indeed significantly better 
than the experiences of his colleagues who reported 
mortalities ranging from 50 to 80%. It should be 
recognized that this extraordinary incidence of mor­
tality was generally accepted in the efforts of devel­
oping intracranial surgery at that time.
As a consequence of these earlier experiences, 
attempts were continually made to modify surgical 
techniques and adjuvant management in an effort to 
make the surgical approach to the pituitary a more 
reasonable option for both surgeon and patient. In 
this light, Schloffer, a rhinologist from Innsbruck, 
Austria, recommended utilization of a transsphe­
noidal route as an alternative and presumably safer 
approach to the sella turcica and its contents. In­
deed, in 1907, he reported the first successful re­
moval of a pituitary tumor using the transsphenoi­
dal approach (138). The technique of sphenoid sinus 
exposure subsequently underwent a number of 
modifications by interested surgeons, and the cul­
mination was Halstead’s description in 1910 of the 
sublabial gingival incision for the initial stage of 
sphenoid sinus exposure. After initial disappoint­
ments at transcranial efforts, Cushing himself em­
braced the transsphenoidal approach. He described 
a technique that combined a number of suggestions 
made by previous authors and employed the subla­
bial incision described by Halstead (Fig. 1). Cush­
ing also adopted the technique of submucous dis­
section of the nasal septum promulgated by Eisel- 
berg and Kocher and em ployed the headlight 
described by Kanavel to enable better visualization 
in the depths of the operative field during surgery. 
Utilizing the transnasal/transsphenoidal approach 
during the 15-year period from 1910 to 1925, Cush­
ing operated on some 231 pituitary tumors with a 
reported mortality of 5.6%. This certainly repre­
sented the best efforts at surgical exposure and ac­
cess to the pituitary at the time (139).
Mortality and morbidity from use of the trans­
sphenoidal approach related primarily to infection 
that was frequently associated with postoperative 
CSF rhinorrhea; on the other hand, hemorrhage and 
postoperative edema underlay the excessive mor­
tality and morbidity experienced with transcranial 
approaches. However, as Cushing developed in­
creasing expertise and confidence in transcranial 
surgery, he again began to utilize the transcranial 
approach to the pituitary. As he gained experience, 
Cushing finally reduced his mortality with the trans­
cranial approach to 4.5%, essentially eliminating 
any significant differential between the mortalities
experienced with transsphenoidal and transcranial 
approaches. It was his opinion that visual recovery 
was more complete following direct decompres­
sion of the optic nerves and chiasm which may cer­
tainly have been the case in those early times. In 
addition, Cushing recognized that the transfrontal 
approach allowed more extensive resection of those 
suprasellar tumors complicated by significant later­
al extension (139). Obviously, Dr. Cushing’s in­
tense interest in intracranial surgery must have 
contributed to his pursuit and development of trans­
cranial approaches to the pituitary. Other distin­
guished surgeons, however, such as Hirsch (140) 
and Hamlin (141), continued to use the transsphe­
noidal approach with reports of excellent results. It 
is reported that Dr. Cushing, on the occasion of 
his 70th birthday, remarked that the transsphenoi­
dal approach, because of its many advantages, 
would probably return despite the liabilities he per­
ceived.
Because of the dominance of Cushing in the evo­
lution of neurosurgery in the United States and the 
outstanding results that he reported, the utilization 
of transsphenoidal operations on the pituitary di­
minished profoundly during this period until Nor­
man Dott of Edinburgh, a student of Cushing, refo­
cused attention on this technique (142). In turn, 
Dott reportedly introduced Guiot of France (143) to 
the technique of transsphenoidal approach to the 
pituitary, and Guiot subsequently influenced the ex­
tensive development of this technique by Jules 
Hardy of Montreal (144). Accumulating an exten­
sive experience in transsphenoidal microsurgery, 
these individuals significantly altered and redefined 
the indications and risks related to the transsphe­
noidal resection of hypophyseal and parahypophy- 
seal tumors. In addition, refinement of the tech­
niques for closure of the opening between the sphe­
noid sinus and the intracranial compartment has 
resulted in a profound decrease in the mortality and 
morbidity associated with this procedure.
Radical operative procedures involving the hy­
pophysis carried a prohibitive complication rate be­
fore the development of commercially available 
corticosteroids in the early 1950s. Replacement of 
these agents in patients who are rendered hypopi- 
tuitary either by the development of a tumor of 
other mass or as a consequence of surgical extrac­
tion of such lesions is essential for successful sur­
gical intercession; commercial availability of the 
corticoids has truly revolutionized postoperative 
morbidity and mortality in these efforts.
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Any lesion proximal to the pituitary or hypothal­
amus requires adequate endocrine evaluation pre- 
operatively to minimize the potential for an intra­
operative or postoperative catastrophe because of 
inadequate pituitary reserve. The two most impor­
tant of these evaluations are cortisol and thyroid 
levels. Because of the universal use of perioperative 
glucocorticoids in surgery involving this area, the 
risk of intraoperative hypocortisolemia is generally 
not a major factor. However, preexistent hypothy­
roidism may manifest acutely during the early post­
operative period, underlining the need for adequate 
preoperative assessment. In patients with associ­
ated hypothyroidism, reestablishment requires ~1 
week of treatment before any elective surgical pro­
cedure. In the event of concomitant hypocortiso- 
lism, to avoid precipitating an adrenal crisis, the 
cortisol deficiency must be treated before initiating 
thyroid hormone therapy. For this reason, complete 
endocrine evaluation is performed on all patients 
suspected of harboring a pituitary lesion. Of course, 
normalcy preoperatively does not guarantee such a 
state postoperatively, but an understanding of pre­
operative function may indicate those patients in 
whom a risk of this occurrence should be consid­
ered in the perioperative period.
An assessment of electrolyte status is also impor­
tant to define the patient with marginal DI (145-148) 
who may not comment on the long-standing urinary 
frequency from an historical perspective.
Transsphenoidal Approach
As noted previously, the transnasal transsphenoi­
dal approach is currently considered the procedure 
of choice for surgical access to sellar lesions. The 
increase in popularity of this technique may in part 
also be attributed to the well-recognized inade­
quacy of the subfrontal approach to remove the in­
trasellar component of the tumor (149-154). More­
over, several reports exist of favorable results in the 
management of visual disturbances from macroad­
enomas using the transsphenoidal route, establish­
ing this as the approach of choice for the surgical 
management of most pituitary tumors, regardless of 
size (Fig. 2) (150,155). Our assessment of >200 pa­
tients who presented with visual loss from among 
our first 1,000 pituitary patients operated on via the 
transnasal transsphenoidal route yielded evidence 
of improved vision in 81%, unchanged vision in
Preoperative Evaluation
FIG . 2. C hoice o f  surgical app roach : tran ssp h en o id a l versus 
tra n sc ra m a i: 1111s 1 i-w eighted  m agnetic re so n an ce  im age w ith 
gadolinium  enhancem en t d em o n s tra te s  a  large m acroadenom a 
th a t show s m ostly  vertical g row th  w ith no significant m iddle 
fo ssa  ex tension . F o r th is reaso n , a  prim ary  tran ssp h en o id a l ap ­
proach w as chosen  w ith adequate  d ecom pression  o f  th e  visual 
appara tu s.
16%, and worsening of vision in 3%. These results 
are similar to other large series that have been re­
ported concerning the efficacy of the transsphenoi­
dal approach to suprasellar tumors, and these re­
sults certainly equal or exceed the results of large 
series of subfrontal explorations for visual loss. In 
addition, there exists clear documentation of the 
potential for improvement in pituitary function  after 
transsphenoidal adenomectomy with careful preser­
vation of normal gland in cases with preexisting hy­
popituitarism (40,41). The efficacy of transsphenoi­
dal surgery in selected patients with microade­
nomas has been established, with some reports of 
>90% tumor control (129,156). In series including 
larger tumors, however, a less optimistic 50 to 85% 
tumor control is expected with surgery alone (150, 
157,158).
Transsphenoidal microsurgery for both large and 
small adenomas done by experienced surgeons has 
acceptable mortality and morbidity (159). Of 2,606 
microadenomas and 2,677 macroadenomas re­
ported in an international survey by Zervas (66), the 
death rate was 0.27 and 0.86%, respectively. Direct 
injury to the hypothalamus seemed to be the major 
cause of surgical death, with delayed mortality at­
tributed to CSF leaks and their attendant septic 
complications, or by vascular injury. Operative 
morbidity includes persistent or permanent DI, the 
incidence ranging from 1.8% permanent DI in one
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large series (160) to a 17% incidence immediately 
postoperatively with large adenomas (155). Postop­
erative CSF fistulas range from 1 to 4.4% among 
different series, depending on the size of the lesion 
and follow-up time, but occur disproportionately 
with larger lesions (66,161-163). Other major mor­
bidity (stroke, visual loss, vascular injury, meningi­
tis, CSF rhinorrhea, cranial nerve palsy) is encoun­
tered in 3.5%, and minor morbidity (bleeding, nasal 
or sinus problems, DI, syndrome of inappropriate 
antidiuretic hormone, transient cranial nerve pare­
sis, transient psychosis) occurs in another 3.5% of 
patients (164). As put forth by all of these authors, 
complications amount to a relatively small percent­
age of the overall surgical experience, emphasizing 
the relative safety of the procedure.
Although it is the procedure of choice for the ma­
jority of pituitary tumors, the rare relative contrain­
dications to the transsphenoidal approach include 
(a) extensive lateral tumor herniating into the mid­
dle fossa with minimal midline mass (these cases 
may  require a primary or secondary transcranial 
procedure to remove tumor inaccessible by a mid­
line approach); (b) midline projecting ectatic carotid 
arteries that are at risk of injury using a transsphe­
noidal approach (Fig. 3); and (c) acute sinusitis, that 
may delay the procedure for treatment of the infec­
tion. Previous rhinoplasty or submucous resection 
may increase the difficulty developing the dissec­
tion planes, but these can invariably be established. 
Thus these factors should not themselves constitute 
contraindication of the transnasal approach.
A detailed description of the transnasal trans­
sphenoidal procedure performed at our institution 
has been published (162) and is reviewed in Fig. 
4-8. Adequate bony removal is essential to enable 
complete sellar access. The location of the carotid 
arteries on the coronal MRI should be noted; this 
information is valuable when opening the dura at 
the lateral margins of the sella. Characteristically, 
these tumors are soft and friable and at surgery may 
herniate down through the diaphragma sellae af­
ter evacuation of the intrasellar component; this 
may be facilitated by the anesthetist performing a 
Valsalva maneuver intraoperatively. Other tech­
niques to promote tumor descent include the infu­
sion of air or saline through a previously placed 
cisternal or lumbar catheter (38,165). A pure supra­
sellar tumor, or one that requires suprasellar ac­
cess, may be approached, if necessary, by carrying 
the bony resection anterior over the tuberculum 
sellae with exposure of the dura mater lying anterior
FIG . 3. Surgical ap p ro ach es to the  se lla  and  su p rase lla r c is te rn . 
W hen choosing an app ro ach  to  lesions in th is a rea , it is im p o rtan t 
to  no te  the  location  o f  the ca ro tid  a rte rie s  and  th e  d irec tio n  o f  
tu m o r ex ten sio n . T he tran sn asa l tran ssp h en o id a l ap p ro ach  is 
p re fe rred  fo r access to  the  m ajority  o f  p itu itary  ad en o m as. It 
offers d irec t access to  the  se lla  and its c o n ten ts  w ith  no  brain  
re trac tio n  and m inim al m orb id ity . A lthough the  m ajority  o f  cases 
are  su itab le  fo r a  transsp h en o id a l ap p ro ach , la tera l e x ten t o f  tu ­
m or o r  ec ta tic  caro tid  a r te ries  m ay lim it a cce ss  to  th e  tum or. T he 
m ost com m on transcran ia l a lte rn a tiv es are  th e  p terional o r sub- 
fron tal ap p ro ach es .
to the circular sinus. A transverse incision may then 
be made in the dura rostral and caudal to the circu­
lar sinus, with bipolar coagulation and transection 
of the circular sinus. This sinus is a structure con­
tained between the leaves of the dura. Transection 
of the circular sinus then enables exposure of the 
suprasellar cistern itself and provides adequate 
room for surgical resection of tumor in this location.
Once the mass has been resected, attention must 
be paid to obliteration of the CSF fistula if the 
arachnoid has been violated (Fig. 8). During trans­
sphenoidal procedures in which the arachnoid has 
been breached, we routinely harvest a fascia lata 
graft of appropriate size to cover the opening; the 
graft is placed on the intradural side of the opening 
(within the intrasellar compartment), and a small 
piece of Marlex mesh is fashioned to place intrasel­
lar to maintain the apposition of the fascial graft. 
Placement of the fascial graft is critical; the in­
tracranial pressure will tamponade the graft to the 
dura if properly inserted. Before closing, the anes-
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FIG . 4. E xposu re  via the  transsp h en o id a l ap p ro ach . O ne may 
vary  the ex p o su re  from  the su p rase lla r c is te rn  lo th e  low er ciivus 
depending  on  the  tra jec to ry  ch o sen  via ihe iranssnasa! approach . 
The en tire  e x ten t o f  the ciivus m ay be acce ssed  by d irec ting  the 
d issec tion  in terio rly  along the vom er anti the ro o f of' the hard  
palate . S im ilarly , a lesion lying o v e r the (ubercu lum  sellae and 
even the planum  sphenoidal can be ap p ro ach ed  by carry ing  the 
d issec tion  an te rio r  to the sella tu rcica afte r the ro strum  o f the 
sphenoid  has been rescc ted .
thetist is asked to perform a Valsalva maneuver to 
assess the functional integrity of the graft. The 
sphenoid behind this graft is then packed with fat 
obtained at the harvest of the fascial graft to further
FIG . 5. S phenoidal landm arks, A: The p e rp en d icu la r plate o f 
the ethm oid  is a  useful landm ark  to guide th e  surgeon  to  the 
rostrum  o f the sphenoid  sinus. A fter rem oval o f  th e  perp en d ic ­
ular p la te  o f the e thm oid , the sphenoid  sinus o stia  rep re sen t the 
an te rio r  e x ten t o f  sphenoidal ex p o su re . B: K eseclton  o f  (he ro s­
trum  o f the sphenoid  sinus utilizing the  ostia  to  gain acce ss to  the 
sella tu rc ica . If th e  sphenoid  sinus is n o n p n eu m atized , one can 
use a  h igh-speed drill to  gain acce ss to  th e  sella.
FIG . 6 , E xpo su re  o f the  sella . O nce the  rostrum  o f the sphe­
noid has been  reseu led  to allow  v isualiza tion  o f  the full e x ten t of 
the sphenoid , the sphenoid  sinus m ucosa should  be ex en te ra ted , 
w hich will help  con tro l any b leeding from  th is m ucosa as well as 
avoiding th e  po ten tia l fo r a p o sto p e ra tiv e  sphenoid  sinus m uco­
cele . T here  is alm ost alw ays a hony  sep tum  w ithin the sphenoid 
sinus ihat a lso  m us1 be rem oved to  allow  accc ss to  th e  entire  
e x ten t o f  the floor o f  the sella tu rc ica . F re q u en tly , th is septum  is 
som ew hat eccen tric , and  p reo p era tiv e  im aging m ay give an in­
d ication  o f  its location . D issection  along one side o f  the septum  
only  will give com prom ised  ex p o su re  o f  the  floor o f the se lla  with 
resu ltan t com prom ise  to  the ex ten t o f  resec tio n  o f  the intra- o r 
su p rase lla r co n ten ts .
buttress the graft in position. If there is no CSF 
leakage around the graft, the retractor is removed, 
and the posterior nasal pack is placed against the 
sphenoidal opening. We then perform a routine 
lumbar puncture (18 gauge needle) in the recovery 
room and on the first postoperative day to further 
mitigate against the development of persistent fis­
tula. In the unusual case of a postoperative leak 
following this protocol, the decision to return to the 
operating room for a formal repacking is taken early 
to avoid meningitis; little is to be gained by waiting 
in these cases because the relatively avascular graft 
is less prone to spontaneous closure than in the 
posttraumatic situation. It has been our routine
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FIG . 7. In tra se lla r  ex p o su re . O nce the  floor o f  the  sella has 
been rem oved  to identify  at each  lateral boun d ary  the cavernous 
sinus and  th e  c irc u la r  sinus su p e rio rly  (an  op en in g  1.5 cm 
square), the  du ra  is open ine  in a crucia te  fash ion  to  elevate  four 
dural flaps th a t give m axim al su rface a rea  o f  exposu re  in the 
form  o f  a  square.
practice to obtain nasopharyngeal cultures prior to 
prepping of the nose to guide antibiotic coverage 
should a postoperative meningitis occur.
The remarkably low morbidity and mortality as­
sociated with transsphenoidal resection of even 
very large tumors have encouraged our group to 
consider transnasal resection as the preferred pri­
mary approach to virtually all macroadenomas. 
Many of these herniate into the enlarged sella from 
the suprasellar cistern, subfrontal space, and cav­
ernous sinus once the sellar component has been 
evacuated. We have, on rare occasions, found tu­
mors that do not enlarge the sella but grow directly 
into the suprasellar cistern. These may present a 
particular problem; but, by mobilizing normal gland 
and opening through the tuberculum sellae as de­
scribed previously, one can frequently gain access 
to the suprasellar cistern and extract the tumor.
Transcranial Approach
Our experience with pituitary adenomas has en­
abled us to formulate a plan that essentially obvi­
ates the use of a transcranial approach for pituitary 
macroadenomas. On the other hand, there are lim­
ited occasions in which such an approach is desir­
able (165). These instances, as outlined previously, 
are when the transsphenoidal approach is hazard­
ous from the presence of ectatic carotid arteries or 
when the tumor spills over into the middle fossa or 
both middle fossae while leaving a small virtually
FIG . 8. C losure follow ing tu m o r rem oval. O nce the  tu m o r m ass 
has been  resec te d , carefu l a tten tio n  m ust be paid to  c lo su re  in 
the  even t o f  a b reach  o f the  a rach n o id , w hich m ay re su lt in a C S F  
fistu la . If a C S F  leak is recognized  a t o p e ra tio n , a  fasc ia  la ta  graft 
is harv ested . (A) T he fascia  is p laced against the  rem ain ing  pi­
tu itary  gland w ithin the in tra se lla r com p artm en t. (B) P lacem ent 
o f  the  fascia  graft w ithin the sella is c rucial; the  g raft will tam ­
p onade against the dura if p laced  p ro p erly . (C) T his is th en  b u t­
tressed  in place w ith a tailo red  piece o f  M arlex  m esh ju s t  large 
enough to fit inside the se lla r bony open ing . (D) T he M arlex 
m esh m ust be fitted  co rrec tly  to insure graft in tegrity .
normal-sized sella turcica. Such lesions generally 
occur because of an incompetent diaphragma sellae 
that provides the vehicle for superior and lateral 
growth of tumor or possibly extensive anterior and/ 
or posterior growth of tumor without the significant 
or measureable expansion of the sella. Under such 
circumstances, direct visualization of the tumor by 
the transcranial approach may be optimal. In addi­
tion, there are occasional cases in which the con­
sistency of tumor encountered via the transsphenoi­
dal approach defies an adequate resection of tumor 
from this approach. This may require a secondary 
transcranial procedure when inadequate decom­
pression of the optic mechanism has been estab­
lished. If the optic mechanism has been adequately 
decompressed, one would generally use postopera­
tive RT to “ mop-up” any residual tumor that may 
defy resection via the transnasal route.
During the course of transcranial surgery, the sig­
nificant complicating anatomy presents itself pri­
marily related to the vascular supply to the hypo­
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thalamus as well as the optic chiasm and nerves and 
tracts (Fig. 9). Almost all pituitary tumors should lie 
below the arachnoid so that one would want to open 
the arachnoid and then stay below the arachnoid 
plane so as not to potentially compromise the per­
forating vasculature to the optic mechanism as well 
as the hypothalamus. The pterional approach to the 
suprasellar cistern lends itself best for this proce­
dure, but one must recognize that the ipsilateral op­
tic nerve may prevent adequate visualization of tu­
mor extending beneath it when the tumor undergoes 
growth in a lateral direction. The best technique in 
these circumstances is an extensive decompression 
medial to the optic nerve followed by subsequent 
mobilization of the tumor from the lateral compart­
ment underneath the optic nerve from lateral to me­
dial so that one can mobilize this final remnant of 
tumor. Exquisite care must be exercised to attempt 
to visualize the proximal portion of the carotid ar­
tery along with its ophthalmic branch to preserve 
the integrity of these structures while also avoiding 
any disruption of the perforating vessels coming 
from the internal carotid artery to the posterior as­
pect of the optic chiasm as well as optic nerve.
The consistency of the tumor, as from below, is 
usually that of a soft and friable lesion that is easily
Opt", re'.-e 
and ircct
FIG . 9. H a z a rd s  w ith  th e  tra n sc ra n ia l a p p ro a c h . D uring  a 
transcran ia l ex p o su re  fo r a  tu m o r w ith su p rase lla r ex ten sio n , one 
m ust ex erc ise  cau tion  w ith th e  m anipu lation  o f low  m idline n eu ­
ral and v ascu la r s tru c tu re s . T he ab u n d an t perfora ting  a rte ries  in 
th is region pose  a  h azard  to  m anipu la tion  o f  the  a d h e ren t capsu le  
o f  the  p itu itary  tum or.
debulked by the use of curettes of variable lengths 
and rotations. The main difficulty encountered with 
the removal of the lesion is the adherent capsule 
that may preclude total removal without injury to 
cranial nerves or the midline neuraxis. In such 
cases, it is certainly more prudent to remove the 
soft interior and to leave a densely adherent capsule 
than to risk cranial and vascular injury for a lesion 
that is likely not curable by surgery alone. These 
patients invariably need RT for ultimate tumor con­
trol. The goals of the operation should primarily be 
decompression of the optic apparatus and judicious 
tumor removal without exposing neural or vascular 
structures to undue risk of injury.
Perioperative Management
Perioperative glucocorticoids are administered to 
all patients; this is crucial if preoperative endocrine 
assessment indicates any hypocortisolemia. Meth- 
ylprednisolone is given i.v. at sizable dosages of 40 
mg (or 10 mg dexamethasone) every 6 h in the im­
mediate perioperative period in those cases with 
neurological compromise, usually starting the day 
before surgery. Then a dose regimen tailored to the 
individual patient’s projected glucocorticoid needs 
as anticipated by the preoperative endocrine assess­
ment and intraoperative findings is followed. In 
those patients without visual compromise, lower 
dosages of these high-potency glucocorticoids may 
be employed.
Thyroid function, as mentioned previously, 
should be assessed preoperatively and normalized 
before any elective surgical intervention. The stress 
of surgery may provoke an acute crisis in the pa­
tient without sufficient reserve and should be a con­
sideration in patients with an otherwise unexplained 
alteration in mental status postoperatively.
Serial visual field testing is routinely performed in 
the recovery room and ICU to monitor visual and 
general neurological condition. In the patient with 
preoperative visual deficit, careful monitoring in the 
early postoperative period is essential. Both the 
transfrontal and transsphenoidal routes are success­
ful in improving vision. Immediate postoperative 
improvement of vision may occur, with a significant 
improvement usually =^2 weeks, but continued im­
provement may occur for up to 12 months. More 
importantly, any loss of vision in the postoperative 
period may indicate an evolving hemorrhagic com­
plication; in this instance, emergent CT scanning 
should be performed to exclude this. Evidence of
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hemorrhage on the postoperative scan with a pro­
gressive visual deficit warrants emergent transsphe­
noidal reexploration.
Blood pressure is carefully monitored; hypoten­
sive events are to be avoided, especially in cases 
with compressive neurological deficit in which tis­
sue perfusion is already marginal.
Urine volumes and specific gravities must be fol­
lowed in concert with sodium levels to clearly un­
derstand the dynamics of potential postoperative 
DI. Manipulation of the normal posterior pituitary 
gland may produce transient fluctuations in urine 
output.
Before discharge, an a.m. fasting serum cortisol 
is obtained to determine the need for cortisol re­
placement. Intraoperative evidence of residual nor­
mal pituitary gland is also a major guide in such 
considerations. Thyroid evaluation is usually done 
3 to 4 weeks postoperatively because autonomous 
function of the thyroid may persist for some time 
postoperatively.
Unless clinically indicated, postoperative imag­
ing is not performed for at least 6 weeks postoper­
atively—3 months in most cases. This allows clear­
ance of all operative artefactual changes that might 
confuse one’s decision about the implementation of 
postoperative adjuvant therapy.
RADIOTHERAPY FOR PITUITARY ADENOMAS 
Postoperative RT
The rationale for the use of postoperative RT is to 
reduce the incidence of recurrence; several studies 
suggest improved tumor control with the combina­
tion of surgery plus RT (158,167,168). This is espe­
cially true in large and invasive lesions, which man­
ifest an increased rate of recurrence. This treatment 
does not ensure recurrence-free survival, but the 
time to recurrence may be prolonged. Valtonen and 
Myllymaki (169) have reported a surprisingly high 
36% recurrence rate in patients with a “ total re­
moval” following transfrontal craniotomy and post­
operative RT, with recurrences occurring s*18 
years after therapy. Thus, published recurrence 
rates may be misleading in series with short follow- 
up times. This is an important consideration; mor­
bidity and mortality both increase with operative 
intervention in cases of recurrence (169,170).
With functioning pituitary tumors, evaluation of 
postoperative endocrine status may give indication 
about the effectiveness of the surgical removal;
however, in nonfunctioning lesions, the judgment of 
the surgeon supplemented by postoperative imaging 
are the only parameters to gauge the extent of re­
section and therefore risk of recurrence. The sur­
geon’s appreciation of the totality of the resection 
may not be accurate in the face of an invasive tu­
mor. The lack of a chemical marker in a true non­
functional tumor makes assessment of cure difficult 
in the postoperative period. Furthermore, in con­
trast to PRL- and GH-secreting tumors, no adjunc­
tive pharmacotherapy is available.
For these reasons, the criteria for selection of 
patients for postoperative RT remains controver­
sial. In general, large tumors, which have a high 
frequency of invasion of the cavernous sinus and 
dura and therefore defy complete surgical excision, 
should all be considered candidates for postopera­
tive RT, especially if the patient is hypopituitary 
postoperatively. Similarly, with frank cavernous si­
nus invasion, postoperative RT is advocated. In 
those cases where tumor invasion is not evident and 
“ total” removal has been achieved, following the 
patient with routine scanning on a yearly basis may 
be an appropriate strategy, especially if endocrine 
function is intact.
The recent development of stereotactic radiosur­
gery (image-directed focal RT) may provide a safer 
and more effective method of RT for pituitary ade­
nomas. Focused RT may potentially avoid damage 
to midline neural and vascular structures while de­
livering high local therapeutic doses to the lesion 
with great accuracy. Results from current ongoing 
clinical trials are forthcoming.
Primary RT
RT was advocated for the management of pitu­
itary tumors as early as 1907 (138). In the elderly 
patient or any patient harboring a medical illness 
that may pose a significant risk to general anesthe­
sia and surgery, consideration should be given to 
primary RT, after an appropriate clinical diagnosis 
of a pituitary tumor. Fortunately, with the ex­
tremely low morbidity and mortality rates reported 
in published series from experienced surgeons, the 
number of patients referred for primary RT is low. 
The indications for this nonsurgical approach 
strengthen in cases with hypopituitarism.
Reported series of patients treated with RT alone 
describe a 50% recurrence rate with a 75% local 
control following salvage treatment (158). Other au­
thors report a local control rate of 50 to 79%, with
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an adequate salvage in cases of recurrence (171, 
172). A dose of 4000 Gy by external beam is con­
sidered optimal by most radiotherapists (173,174). 
Recently it has been suggested that late recurrence 
after RT, which occurs not uncommonly, may be 
the result of inadequate dosage, Treatments with 
4500 Gy given in 25 fractions have been reported to 
result in a high (>90%) probability of stable long­
term control (175).
RT, however, should not be considered a com­
pletely benign therapy or an equivalent alternative 
to microsurgical resection. Adverse effects from ra­
diation in this region may range from mild to severe. 
It carries a significant risk of worsening preexisting 
hypopituitarism, with an overt 10 to 15% frequency 
of panhypopituitarism (168). It may increase the 
rate ofatherogenesis in the major vessels in the field 
and cause visual impairment (158). These complica­
tions increase as a function of total treatment dose 
(173). The visual impairment may result from one of 
several mechanisms, including empty sella syn­
drome, treatment failure, or direct radiation damage 
to optic pathways. This latter complication is seen 
with significant frequency with daily fractionation 
>220 Gy (173). Other minor complications from RT 
include epilation, scalp swelling, and otitis (176).
A c k n o w le d g m e n t: P o r t io n s  o f  th is  p a p e r  w e re  a d a p te d  
f ro m  r e f e r e n c e s  4 3 , 9 0 , a n d  166.
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